The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

Jose R Arribas; Andrzej Horban; Jan Gerstoft; Gerdt Fätkenheuer; Mark Jason Nelson; Nathan Clumeck; Federico Pulido; Andrew Hill; Yvon van Delft; Thomas Stark; Christiane Moecklinghoff

doi:10.1097/QAD.0b013e3283348944

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

Jose R Arribas, Andrzej Horban, Jan Gerstoft, Gerdt Fätkenheuer, Mark Jason Nelson, Nathan Clumeck, Federico Pulido, Andrew Hill, Yvon van Delft, Thomas Stark, Christiane Moecklinghoff

178 Citations (Scopus)

Abstract

In virologically suppressed patients, darunavir-ritonavir (DRV/r) monotherapy could maintain virological suppression similarly to DRV/r and two nucleosides.

Original language	English
Journal	AIDS
Volume	24
Issue number	2
Pages (from-to)	223-30
Number of pages	8
DOIs	https://doi.org/10.1097/QAD.0b013e3283348944
Publication status	Published - 16 Jan 2010

Access to Document

10.1097/QAD.0b013e3283348944

Cite this

@article{7be07b86366a4c20b911b0c577d26126,

title = "The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml",

abstract = "In virologically suppressed patients, darunavir-ritonavir (DRV/r) monotherapy could maintain virological suppression similarly to DRV/r and two nucleosides.",

author = "Arribas, \{Jose R\} and Andrzej Horban and Jan Gerstoft and Gerdt F{\"a}tkenheuer and Nelson, \{Mark Jason\} and Nathan Clumeck and Federico Pulido and Andrew Hill and \{van Delft\}, Yvon and Thomas Stark and Christiane Moecklinghoff",

year = "2010",

month = jan,

day = "16",

doi = "10.1097/QAD.0b013e3283348944",

language = "English",

volume = "24",

pages = "223--30",

journal = "AIDS",

issn = "1473-5571",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

AU - Arribas, Jose R

AU - Horban, Andrzej

AU - Gerstoft, Jan

AU - Fätkenheuer, Gerdt

AU - Nelson, Mark Jason

AU - Clumeck, Nathan

AU - Pulido, Federico

AU - Hill, Andrew

AU - van Delft, Yvon

AU - Stark, Thomas

AU - Moecklinghoff, Christiane

PY - 2010/1/16

Y1 - 2010/1/16

N2 - In virologically suppressed patients, darunavir-ritonavir (DRV/r) monotherapy could maintain virological suppression similarly to DRV/r and two nucleosides.

AB - In virologically suppressed patients, darunavir-ritonavir (DRV/r) monotherapy could maintain virological suppression similarly to DRV/r and two nucleosides.

UR - https://www.scopus.com/pages/publications/74249086332

U2 - 10.1097/QAD.0b013e3283348944

DO - 10.1097/QAD.0b013e3283348944

M3 - Journal article

C2 - 20010070

SN - 1473-5571

VL - 24

SP - 223

EP - 230

JO - AIDS

JF - AIDS

IS - 2

ER -

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

Abstract

Access to Document

Other files and links

Fingerprint

Cite this